These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 1294860)

  • 1. Investigation of the pharmacokinetic behavior of barucainide in man during an early phase I study.
    Brode E; Müller-Peltzer H; Indest H
    Methods Find Exp Clin Pharmacol; 1992 Nov; 14(9):717-24. PubMed ID: 1294860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerance of the new class IB antiarrhythmic barucainide: an intravenous dose-finding study.
    Zehender M; Meinertz T; Hohnloser S; Geibel A; Just H
    Clin Pharmacol Ther; 1991 Jan; 49(1):78-85. PubMed ID: 1988242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
    Cheng JW; Charland SL; Goldfarb S; Spinler SA
    Clin Pharmacol Ther; 1995 May; 57(5):492-8. PubMed ID: 7768071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experimental and initial clinical experiences with the new class Ib anti-arrhythmia agent barucainide].
    Gülker H; Heuer H; Frenking B; Haverkamp W; Hindricks G; Bozek B; Bremkes C; Asche KD; Witthöft D
    Z Kardiol; 1988 Sep; 77(9):587-94. PubMed ID: 2461620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of cicletanine in healthy volunteers.
    Pruñonosa J; Peraire C; Torrent J; Obach R
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):265-70. PubMed ID: 1526688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.
    Visser M; Holinka CF; Coelingh Bennink HJ
    Climacteric; 2008; 11 Suppl 1():31-40. PubMed ID: 18464021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of barucainide on left ventricular ejection fraction in patients with ventricular cardiac arrhythmias].
    Scheininger M; Dziersk J; Kullak W; Kors A; Köhler JA; Theisen K
    Z Kardiol; 1991 Oct; 80(10):630-6. PubMed ID: 1722935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function.
    Tuininga YS; Crijns HJ; Oosterhuis B; Wiesfeld AC; van Wijk LM; Albronda F; de Bruin H; Jonkman JH; Kozma C; Lie KI
    J Cardiovasc Pharmacol; 1994 Mar; 23(3):408-14. PubMed ID: 7515984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study.
    Pettersen RJ; Salem M; Skorve J; Ulvik RJ; Berge RK; Nordrehaug JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):410-7. PubMed ID: 18427285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.
    Weinling E; McDougall S; Andre F; Bianchetti G; Dubruc C
    Fundam Clin Pharmacol; 2006 Aug; 20(4):397-403. PubMed ID: 16867025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist.
    Upward JW; Arnold BD; Link C; Pierce DM; Allen A; Tasker TC
    Eur J Cancer; 1990; 26 Suppl 1():S12-5. PubMed ID: 2169778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of brodimoprim.
    Weidekamm E
    J Chemother; 1993 Dec; 5(6):475-9. PubMed ID: 8195840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.